Eli Lilly and Company (LLY) stock analysis

Eli Lilly and Company — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 8.4/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Eli Lilly and Company shows trailing revenue of $79.67B, a 83.4% gross margin, net debt of $36.05B, EPS of 28.80, valued at about 12.5x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $1115.70
• YTD Return: +3.3%
• Revenue TTM: $79.67B
• Revenue Trend: YoY +47.7%
• Gross Margin: 83.4%
• Net Cash: $-36.05B
• EPS: 28.80
• P/S Ratio: 12.5x

Compare: LLY vs UNH · LLY vs JNJ · LLY vs PFE | Also: UNH, JNJ, PFE, MRK, ABBV, TMO